Eli Lilly slashes Zepbound prices: Check out the updated costs and where to buy the weight-loss drug

Eli Lilly & Co. is once again lowering the price of its introductory Zepbound doses as the battle with Novo Nordisk intensifies. Beginning Monday, the company will charge $299 a month for the lowest-dose vial for cash-pay customers, a reduction of about $50. The next dose up will be priced at $399 a month, roughly 20% below its previous self-pay cost. Prices for the higher-dose options remain unchanged at $499 a month.

The move marks the latest escalation in the ongoing price war between Lilly and Denmark-based Novo Nordisk, both racing to make it cheaper for patients to begin treatment with these blockbuster weight-loss drugs. Novo reduced its own cash-pay prices in November, bringing the introductory two-month supply of Ozempic and Wegovy down to $199 on the NovoCare portal before rising to $349 a month. Lilly’s new discounts are available through LillyDirect, its direct-to-consumer platform, where most patients begin at lower doses before gradually moving to higher strengths for additional weight loss.


Ilya Yuffa, president of Lilly USA, said the updated pricing reflects the company’s commitment to expanding access to obesity medications. This marks the second time this year that Lilly has reduced Zepbound vial prices on its LillyDirect platform. “We will keep working to provide more options – expanding choices for delivery devices and creating new pathways for access – so more people can get the medicines they need,” he said in a statement.


The drugmaker is offering savings of up to 20% on certain cash-pay prices


Source: Lilly
Both Novo and Lilly are aggressively competing for dominance in the rapidly growing global obesity market, which analysts forecast could reach $100 billion by the end of the decade. Their strategies increasingly include expanded discount programs for cash-pay customers, deeper partnerships with pharmacy benefit managers, and new direct-to-employer offerings designed to capture long-term users.

At the same time, pricing pressure is mounting from the Trump administration’s broader push to reduce drug costs. On Tuesday, the White House announced it had secured a 71% discount on Ozempic and Wegovy for Medicare patients, with those price cuts scheduled to take effect in 2027.

Separately, both companies struck a deal with the administration to reduce their U.S. pricing across Medicare and self-pay markets. As part of that agreement, Lilly will also lower the cost of its Zepbound multidose pens. Those changes are scheduled to begin in 2026.


Get an chance to win ₹5000 Amazon Voucher by taking part in India's Biggest Habit Index! Take the survey here